BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target
BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.
Stocks · News reference
Ginkgo Bioworks Announces Ginkgo Datapoints Agreement With Eli Lilly's TuneLab To Provide Small Molecule And Antibody Developability Testing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience joins Eli Lilly's TuneLab platform, supplying high-throughput antibody data to train advanced AI drug prediction models.
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength
Shares of Eli Lilly and Company are trading higher Tuesday following positive previews of its late-stage obesity and diabetes pipeline.
Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.